The effect of preexisting anti-carrier immunity on subsequent responses to CRM₁₉₇ or Qb-VLP conjugate vaccines

References

• Gasparini R, Panatto D. Meningococcal glycoconjugate vaccines. Hum Vaccin 2011;7:170–182.
   PubMed Web of Science ®Google Scholar
• Update: prevention of Haemophilus influenzae type b disease. Morb Mortal Wkly Rep 1988;37:13–16.
   PubMedGoogle Scholar
• Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother 2013;9:2505–2523.
   PubMed Web of Science ®Google Scholar
• Forsgren A, Riesbeck K, Janson H. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis 2008;46:726–731.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Therapeutic vaccines for chronic diseases: successes and technical challenges. Philos Trans R Soc Lond B Biol Sci 2011;366:2815–2822.
   PubMed Web of Science ®Google Scholar
• Kantele A, Hakkinen MP, Zivny J, et al. Humoral immune response to keyhole limpet haemocyanin, the protein carrier in cancer vaccines. Clin Dev Immunol 2011;614383.
   PubMedGoogle Scholar
• Cerny EH, Levy R, Mauel J, et al. Preclinical development of a vaccine ‘against smoking’. Onkologie 2002;25:406–411.
   PubMed Web of Science ®Google Scholar
• Hatsukami DK, Rennard S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005;78:456–467.
   PubMed Web of Science ®Google Scholar
• Hatsukami DK, Jorenby DE, Gonzales D, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 2011;89:392–399.
   PubMed Web of Science ®Google Scholar
• Szu SC, Lin KF, Hunt S, et al. Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine. Vaccine 2014;32:2618–2622.
   PubMed Web of Science ®Google Scholar
• Tontini M, Berti F, Romano MR, et al. Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines. Vaccine 2013;31:4827–4833.
   PubMed Web of Science ®Google Scholar
• Shah S, Raghupathy R, Singh O, et al. Prior immunity to a carrier enhances antibody responses to hCG in recipients of an hCG-carrier conjugate vaccine. Vaccine 1999;17:3116–3123.
   PubMed Web of Science ®Google Scholar
• Schutze MP, Leclerc C, Jolivet M, et al. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol 1985;135:2319–2322.
   PubMed Web of Science ®Google Scholar
• Peeters CC, Tenbergen-Meekes AM, Poolman JT, et al. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun 1991;59:3504–3510.
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Wiesel M, Dietmeier K, et al. Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine 2010;28:5503–5512.
   PubMed Web of Science ®Google Scholar
• Jalah R, Torres OB, Mayorov AV, et al. Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers. Bioconjug Chem 2015;26:1041–1053.
   PubMed Web of Science ®Google Scholar
• Borrow R, Dagan R, Zepp F, et al. Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev Vaccines 2011;10:1621–1631.
   PubMed Web of Science ®Google Scholar
• Herzenberg LA, Tokuhisa T, Herzenberg LA. Carrier-priming leads to hapten-specific suppression. Nature 1980;285:664–667.
   PubMed Web of Science ®Google Scholar
• Herzenberg LA, Tokuhisa T, Parks DR, Herzenberg LA. Epitope-specific regulation. II. A bistable, IgH-restricted regulatory mechanism central to immunologic memory. J Exp Med 1982;155:1741–1753.
   PubMed Web of Science ®Google Scholar
• Herzenberg LA, Tokuhisa T. Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses. J Exp Med 1982;155:1730–1740.
   PubMed Web of Science ®Google Scholar
• Schutze MP, Deriaud E, Przewlocki G, Leclerc C. Carrier-induced epitopic suppression is initiated through clonal dominance. J Immunol 1989;142:2635–2640.
   PubMed Web of Science ®Google Scholar
• Pobre K, Tashani M, Ridda I, et al. Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines. Vaccine 2014;32:1423–1430.
   PubMed Web of Science ®Google Scholar
• Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: a review. Vaccine 2010;28:5513–5523.
   PubMed Web of Science ®Google Scholar
• Broker M, Costantino P, DeTora L, et al. Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals 2011;39:195–204.
   PubMed Web of Science ®Google Scholar
• Ambuhl PM, Tissot AC, Fulurija A, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007;25:63–72.
   PubMed Web of Science ®Google Scholar
• Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008;3:e2547.
   PubMed Web of Science ®Google Scholar
• Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 2005;35:2031–2040.
   PubMed Web of Science ®Google Scholar
• Maurer P, Bachmann MF. Immunization against angiotensins for the treatment of hypertension. Clin Immunol 2010;134:89–95.
   PubMed Web of Science ®Google Scholar
• van den BM, Bachmann MF, Kohler G, et al. IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-gamma and nitric oxide synthetase 2. J Immunol 2000;164:371–378.
   PubMed Web of Science ®Google Scholar
• Pryde DC, Jones LH, Gervais DP, et al. Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice. PLoS One 2013;8:e76557.
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Thorn J, Mehelic PR, et al. Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates. Int Immunopharmacol 2015;25:518–527.
   PubMed Web of Science ®Google Scholar
• Gruber WC, Scott DA, Emini EA. Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine. Ann NY Acad Sci 2012;1263:15–26.
   PubMed Web of Science ®Google Scholar
• Vollmer J, Weeratna R, Payette P, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004;34:251–262.
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Pryde DC, Gervais DP, et al. Enhancing immunogenicity of a 3′aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. Int Immunopharmacol 2013;16:50–56.
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Jacob P. III. Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 1984;35:499–504.
   PubMed Web of Science ®Google Scholar
• Pecetta S, Lo SP, Tontini M, et al. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation. Vaccine 2015;33:314–320.
   PubMed Web of Science ®Google Scholar
• Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11:263–270.
   PubMed Web of Science ®Google Scholar
• Forsbach A, Nemorin JG, Montino C, et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol 2008;180:3729–3738.
   PubMed Web of Science ®Google Scholar
• Forsbach A, Nemorin JG, Volp K, et al. Characterization of conserved viral leader RNA sequences that stimulate innate immunity through TLRs. Oligonucleotides 2007;17:405–417.
   PubMedGoogle Scholar
• Nguyen DN, Mahon KP, Chikh G, et al. Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proc Natl Acad Sci USA 2012;109:E797–E803.
   PubMed Web of Science ®Google Scholar
• Jennings GT, Bachmann MF. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 2009;49:303–326.
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Maurer P, Bessa J, et al. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 2007;178:2415–2420.
   PubMed Web of Science ®Google Scholar
• Zoller M, Andrighetto G. Regulation of carrier-specific response via a haptenic epitope. Scand J Immunol 1987;26:277–286.
   PubMed Web of Science ®Google Scholar
• Miller KD, Roque R, Clegg CH. Novel anti-nicotine vaccine using a trimeric coiled-coil hapten carrier. PLoS One 2014;9:e114366.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Osaka Y, Banri-Koike C, et al. T cells specific to hapten carrier but not to carrier alone assist in the production of anti-hapten and anti-carrier antibodies. Int Immunol 2007;19:1157–1164.
   PubMed Web of Science ®Google Scholar
• Jalah R, Torres OB, Mayorov AV, et al. Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers. Bioconjug Chem 2015;26:1041–1053.
   PubMed Web of Science ®Google Scholar
• Chuan YP, Rivera-Hernandez T, Wibowo N, et al. Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine. Biotechnol Bioeng 2013;110:2343–2351.
   PubMed Web of Science ®Google Scholar
• de Villiers SH, Cornish KE, Troska AJ, et al. Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine 2013;31:6185–6193.
   PubMed Web of Science ®Google Scholar
• Cornish KE, de Villiers SH, Pravetoni M, Pentel PR. Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions. PLoS One 2013;8:e82557.
   PubMed Web of Science ®Google Scholar
• Putz MM, Ammerlaan W, Schneider F, et al. Humoral immune responses to a protective peptide-conjugate against measles after different prime-boost regimens. Vaccine 2004;22:4173–4182.
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Thorn J, Gervais DP, et al. Anti-nicotine vaccines: comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates. Int Immunopharmacol 2015;29:663–671.
   PubMed Web of Science ®Google Scholar
• Zhang T, Yu W, Wang Y, Hu T. Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine. Vaccine 2015;33:3208–3214.
   PubMed Web of Science ®Google Scholar
• Rosenberg JB, De BP, Hicks MJ, et al. Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine. Hum Gene Ther 2013;24:595–603.
   PubMed Web of Science ®Google Scholar